Blisibimod, an investigational anti-BAFF molecule in Phase III trails for the treatment of systemic lupus erythematosus and Phase II trials for the treatment of IgA nephropathy.
Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS).
Torrent Pharmaceuticals | Emcure Pharmaceuticals | Barr Pharmaceuticals | Valeant Pharmaceuticals | Reata Pharmaceuticals | Millennium Pharmaceuticals | Anthera Pharmaceuticals | Quark Pharmaceuticals | Norwich Pharmaceuticals | Incepta Pharmaceuticals | Glenmark Pharmaceuticals |
Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus.